Literature DB >> 31167817

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Ashraf Z Badros1, Ning Ma1, Aaron P Rapoport1, Emily Lederer1, Alexander M Lesokhin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31167817      PMCID： PMC6560349          DOI： 10.1182/bloodadvances.2019000191

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  8 in total

1.  Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

Authors:  Matthew D Hellmann; Mark G Kris; Charles M Rudin
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

Authors:  Nicole J Gormley; Richard Pazdur
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

4.  Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

Authors:  Guillaume Manson; Charles Herbaux; Pauline Brice; Krimo Bouabdallah; Aspasia Stamatoullas; Jean-Marc Schiano; Hervé Ghesquieres; Laurent Dercle; Roch Houot
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

5.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Authors:  Caroline Robert; Antoni Ribas; Omid Hamid; Adil Daud; Jedd D Wolchok; Anthony M Joshua; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Richard W Joseph; Roxana Dronca; Amita Patnaik; Hassane Zarour; Richard Kefford; Peter Hersey; Jin Zhang; James Anderson; Scott J Diede; Scot Ebbinghaus; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2017-12-28       Impact factor: 44.544

6.  Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Authors:  Ashraf Badros; Elizabeth Hyjek; Ning Ma; Alexander Lesokhin; Ahmet Dogan; Aaron P Rapoport; Mehmet Kocoglu; Emily Lederer; Sunita Philip; Todd Milliron; Cameron Dell; Olga Goloubeva; Zeba Singh
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

7.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Authors:  Valsamo Anagnostou; Mark Yarchoan; Aaron R Hansen; Hao Wang; Franco Verde; Elad Sharon; Deborah Collyar; Laura Q M Chow; Patrick M Forde
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

8.  Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.

Authors:  Omer Ben-Aharon; Racheli Magnezi; Moshe Leshno; Daniel A Goldstein
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777
  8 in total
  2 in total

Review 1.  Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors:  Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 2.  Targeting immune checkpoints in hematological malignancies.

Authors:  Basit Salik; Mark J Smyth; Kyohei Nakamura
Journal:  J Hematol Oncol       Date:  2020-08-12       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.